UNCY, US90466Y2028

Unicycive Therapeutics stock gets a new director as filing advances

Published on 10/07/2026 at 05:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Meredith Manning joined Unicycive Therapeutics' board on October 1, 2026, adding more than 25 years of biopharma experience. Q2 EPS beat consensus by USD 0.41.

UNCY, US90466Y2028, Illustration mit AI erstellt.

Unicycive Therapeutics stock was last at USD 4.23 on Nasdaq on October 6, 2026, with a market capitalization of USD 112.9 million. The company appointed Meredith Manning to its board on October 1, 2026, as it advances its oxylanthanum carbonate filing.

Board adds commercial experience

According to GlobeNewswire on October 1, 2026, Manning joined the board and its Audit, Compensation, and Nominating and Corporate Governance committees. The company said her background includes more than 25 years in global biopharmaceutical operations, including commercial launches and FDA-approved products.

The appointment comes after Unicycive resubmitted its New Drug Application for oxylanthanum carbonate on September 29, 2026. The treatment is being developed for hyperphosphatemia in patients with chronic kidney disease who receive dialysis, while UNI-494 targets conditions related to acute kidney injury.

Quarterly loss beats consensus

MarketBeat reported that Unicycive posted a Q2 2026 earnings-per-share loss of USD 0.06 on August 12, 2026, versus a consensus loss of USD 0.47. The USD 0.41 beat improves the comparison with expectations, but the company remains in development rather than commercial operations.

Structured financial data show a consolidated net loss of USD 1.7 million for Q2 2026, compared with a USD 12.8 million loss in Q1 2026. Cash and cash equivalents stood at USD 44.2 million on June 30, 2026, while operating cash flow was negative USD 7.6 million for the quarter.

Analysts see a wide valuation gap

MarketBeat said seven research firms carried a Moderate Buy consensus, with five Buy ratings, one Hold, and one Sell. The average 12-month target was USD 18.25, which is 331.4 percent above the USD 4.23 Nasdaq price on October 6, 2026.

The same analyst overview listed a USD 15.00 target from Benchmark, up from USD 13.00, and a USD 25.00 target from Guggenheim, down from USD 37.00. Those target changes show how regulatory execution remains central to the valuation case.

Stock remains below yearly high

Unicycive stock was last at USD 4.23 on Nasdaq at 4:00 p.m. ET on October 6, 2026, up USD 0.04, or 0.95 percent, from the prior close. The session range was USD 4.16 to USD 4.30, and volume reached 785,415 shares.

The 52-week range was USD 3.93 to USD 8.74 as of October 6, 2026. A securities class action deadline for lead-plaintiff applications falls on November 2, 2026, according to GlobeNewswire on October 5, 2026.